SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON D.C. 20549

                                   FORM 10-Q

                  QUARTERLY REPORT UNDER SECTION 13 OR 15 (d)
                     OF THE SECURITIES EXCHANGE ACT OF 1934

                      For the quarter ended March 31, 2011

                         Commission File Number 0-10683

                                 HYDROMER, INC.
                                 --------------
             (Exact name of registrant as specified in its charter)
     New Jersey                                                22-2303576
----------------------                                 -------------------------
(State of incorporation)                                    (I.R.S. Employer
                                                            Identification No.)

35 Industrial Pkwy, Branchburg, New Jersey                     08876-3424
------------------------------------------             -------------------------
(Address of principal executive offices)                       (Zip Code)

Registrant's telephone number, including area code:          (908) 722-5000
                                                       -------------------------

Securities registered pursuant to Section 12 (b) of the Act: None

Securities registered pursuant to Section 12 (g) of the Act:

                         Common Stock Without Par Value
                                (Title of class)

   Indicate  by  check  mark  whether  the  registrant (1) has filed all reports
required  to  be filed by Section 13 or 15 (d) of the Securities Exchange Act of
1934  during  the  preceding  12  months  (or  for  such shorter period that the
registrant was required to file such report(s), and (2) has been subject to such
filing requirements for the past 90 days. Yes X  No

   Indicate  by  check mark whether the registrant is a large accelerated filer,
an  accelerated  filer, a non-accelerated filer, or a smaller reporting company.
Large accelerated filer Accelerated filer Non-accelerated filer

Smaller reporting company    X

   Indicate  by check mark whether the registrant is a shell company (as defined
in Rule 12b-2 of the Exchange Act).

Yes            No  X

                 Class                             Outstanding at March 31, 2011
                                                   -----------------------------
        Common                                               4,772,318



                           FORWARD-LOOKING STATEMENTS

This  quarterly  report  on Form 10-Q contains forward-looking statements within
the  meaning of Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934. Forward-looking statements include, among other
things,  business  strategy  and  expectations  concerning  industry conditions,
market  position,  future  operations,  margins,  profitability,  liquidity  and
capital resources. Forward-looking statements generally can be identified by the
use  of  terminology  such  as  "may,"  "will,"  "expect," "intend," "estimate,"
"anticipate" or "believe" or similar expressions or the negatives thereof. These
expectations  are based on management's assumptions and current beliefs based on
currently   available  information.  Although  the  Company  believes  that  the
expectations  reflected  in  such  statements  are  reasonable,  it  can give no
assurance that such expectations will be correct. You are cautioned not to place
undue  reliance  on these forward-looking statements, which speak only as of the
date  of  this  quarterly  report on Form 10-Q and the Company does not have any
obligation  to  update  the forward looking statements. The Company's operations
are  subject  to  a number of uncertainties, risks and other influences, many of
which  are outside its control, and any one of which, or a combination of which,
could  cause  its  actual  results  of  operations to differ materially from the
forward-looking statements.
<page>

                                 HYDROMER, INC.


                               INDEX TO FORM 10-Q
                                 March 31, 2011

                                                                        Page No.
Part I - Financial Information

   # 1  Consolidated Financial Statements

   Balance Sheets - March 31, 2011 & June 30, 2010                             3

   Statements of Operations for the three months and nine months ended         4
        March 31, 2011 and 2010

   Statements of Cash Flows for the nine months ended                          5
        March 31, 2011 and 2010

   Notes to Financial Statements                                               6

   # 2  Management's Discussion and Analysis of the Financial Condition
        and Results of Operations                                              7

   # 3  Controls and Procedures                                                9


Part II  -  Other Information

   # 1  Legal Proceedings                                                    N/A

   # 2  Change in Securities                                                 N/A

   # 3  Default of  Senior Securities                                        N/A

   # 4  Submission of Motion to Vote of Security Holders                     N/A

   # 5  Other Information                                                    N/A

   # 6  Exhibits                                                               9


                                 EXHIBIT INDEX

Exhibit No.   Description of Exhibit
-----------   ----------------------
31.1          SEC Section 302 Certification - CEO certification               10
31.2          SEC Section 302 Certification - CFO certification               11

32.1          Certification of Manfred F. Dyck, Chief Executive Officer,
              pursuant to 18 U.S.C. Section 1350                              12

32.2          Certification of Robert Y. Lee, Chief Financial Officer,
              pursuant to 18 U.S.C. Section 1350                              12























<page>
PART I - CONSOLIDATED FINANCIAL STATEMENTS
ITEM # 1

                   HYDROMER, INC. AND CONSOLIDATED SUBSIDIARY
                          CONSOLIDATED BALANCE SHEETS
<TABLE>
<S>                                                                                           <C>              <C>


                                                                                                March 31,         June 30,

                                                                                                   2011              2010

                                                                                                UNAUDITED
ASSETS
Current Assets:
  Cash and cash equivalents                                                                   $   872,061      $   843,610
  Short-term investments                                                                                -          440,000
  Trade receivables less allowance for doubtful accounts of $28,565 and $33,276 as of
    March 31, 2011 and June 30, 2010, respectively                                                709,462          920,252
  Inventory                                                                                       301,985          248,569
  Prepaid expenses                                                                                222,921          227,338
  Other                                                                                            16,219           15,487
--------------------------------------------------------------------------------------------------------------------------
Total Current Assets                                                                            2,122,648        2,695,256
--------------------------------------------------------------------------------------------------------------------------

Property and equipment, net                                                                     2,928,940        2,988,536
Deferred tax asset, non-current                                                                 1,213,669        1,011,945
Intangible assets, net                                                                            837,766          839,722
--------------------------------------------------------------------------------------------------------------------------
Total Assets                                                                                  $ 7,103,023      $ 7,535,459
--------------------------------------------------------------------------------------------------------------------------

LIABILITIES AND STOCKHOLDERS' EQUITY
Current Liabilities:
     Accounts payable                                                                         $   387,610      $   342,030
     Accrued expenses                                                                             275,087          251,276
     Current portion of capital lease                                                              17,253           16,000
     Current portion of deferred revenue                                                          189,413           75,828
     Current portion of mortgage payable                                                           50,847           48,800
--------------------------------------------------------------------------------------------------------------------------
Total Current Liabilities                                                                         920,210          733,934
--------------------------------------------------------------------------------------------------------------------------
Deferred tax liability                                                                            283,375          318,375
Long-term portion of capital lease                                                                 21,072           34,716
Long-term portion of deferred revenue                                                             147,092          165,813
Long-term portion of mortgage payable                                                           2,728,463        2,769,036
--------------------------------------------------------------------------------------------------------------------------
Total Liabilities                                                                               4,100,212        4,021,874
--------------------------------------------------------------------------------------------------------------------------

Stockholders' Equity
     Preferred stock - no par value, authorized 1,000,000 shares, no
        shares issued and outstanding                                                                   -                -
     Common stock - no par value, authorized 15,000,000 shares;
        4,783,235 shares issued and 4,772,318 shares outstanding as
        of March 31, 2011 and June 30, 2010                                                     3,721,815        3,721,815
     Contributed capital                                                                          633,150          633,150
     Accumulated deficit                                                                       (1,346,014)        (835,240)
     Treasury stock, 10,917 common shares at cost                                                  (6,140)          (6,140)
--------------------------------------------------------------------------------------------------------------------------
Total Stockholders' Equity                                                                      3,002,811        3,513,585
--------------------------------------------------------------------------------------------------------------------------
Total Liabilities and Stockholders' Equity                                                    $ 7,103,023      $ 7,535,459
--------------------------------------------------------------------------------------------------------------------------
</TABLE>


                                                  See accompanying notes








<PAGE>

                   HYDROMER, INC. AND CONSOLIDATED SUBSIDIARY
                     CONSOLIDATED STATEMENTS OF OPERATIONS
<TABLE>
<S>                                                      <C>              <C>             <C>              <C>



                                                               Three Months Ended                Nine months Ended
                                                                    March 31,                        March 31,
                                                               2011            2010              2011            2010
                                                            UNAUDITED        UNAUDITED          UNAUDITED       UNAUDITED
---------------------------------------------------------  -----------------------------    ------------------------------
REVENUES
    Sale of Products                                     $   1,070,400    $    845,734    $    2,281,134   $   2,856,840
    Service Revenues                                           274,326         402,766         1,044,715       1,062,049
    Royalties and Contract Revenues                            206,316         226,668           687,210         681,964
                                                           -------------    ------------    --------------   -------------
         TOTAL REVENUEs                                      1,551,042       1,475,168         4,013,059       4,600,853
---------------------------------------------------------  -----------------------------    ------------------------------
EXPENSES
   Cost of Sales                                               483,068         526,601         1,231,650       1,994,058
   Operating Expenses                                        1,101,305       1,316,952         3,378,516       3,804,805
   Other Expenses                                               58,961          56,973           157,523         138,611
   Gain from Sale of Assets                                          -               -                 -        (335,629)
  (Benefit) from Income Taxes                                   (34,424)       (218,942)         (243,856)       (445,051)
                                                           -------------    ------------    --------------   -------------
        Total Expenses                                       1,608,910       1,681,584         4,523,833       5,156,794
---------------------------------------------------------  -----------------------------    ------------------------------
        NET LOSS                                         $     (57,868)   $   (206,416)   $     (510,774)  $    (555,941)
---------------------------------------------------------  -----------------------------    ------------------------------

        Loss Per Common Share                            $       (0.01)   $      (0.04)   $        (0.11)  $       (0.12)

Weighted Average Number of
    Common Shares Outstanding                                4,772,318       4,772,318         4,772,318       4,772,318
</TABLE>





                            See accompanying notes.

            There was no impact to earnings per share from dilutive
                  securities as the resultant would have been
                                 anti-dilutive.































<PAGE>

                   HYDROMER, INC. AND CONSOLIDATED SUBSIDIARY
                     CONSOLIDATED STATEMENTS OF CASH FLOWS
<TABLE>
<S>                                                                            <C>             <C>



                                                                                       Nine months Ended
                                                                                           March 31,
                                                                                     2011            2010
                                                                                   UNAUDITED      UNAUDITED
         -----------------------------------------------------------------------------------------------------
         CASH FLOWS FROM OPERATING ACTIVITIES:
             Net Loss                                                          $    (510,774)  $    (555,941)
         Adjustments to reconcile net loss to net cash used for

             operating activities
                Gain on sale of product lines                                              -        (335,629)
                Depreciation and amortization                                        303,122         318,126
                Deferred income taxes                                               (243,856)       (421,417)
                Changes in Assets and Liabilities:
                  Trade receivables                                                  210,790         187,254
                  Inventory                                                          (53,416)         75,296
                  Prepaid expenses                                                       600           9,611
                  Other assets                                                         6,400         (18,402)
                  Accounts payable and accrued liabilities                            69,511          67,118
                  Deferred income                                                     94,864          17,114
                  Income taxes payable                                                     -         (89,212)
         -----------------------------------------------------------------------------------------------------
                      Net Cash Used in Operating Activities                         (122,759)       (746,082)
         -----------------------------------------------------------------------------------------------------

         CASH FLOWS FROM INVESTING ACTIVITIES:
             Cash purchases of property and equipment                               (110,254)       (175,486)
             Cash payments on patents and trademarks                                (140,010)       (251,389)
             Redemption of matured short-term investments                            440,000         700,000
             Cash purchases of short-term investments                                      -        (690,000)
             Proceeds Received from the sale of Product Lines                              -         800,000
         -----------------------------------------------------------------------------------------------------
                      Net Cash Provided by Investing Activities                      189,736         383,125
         -----------------------------------------------------------------------------------------------------

         CASH FLOWS FROM FINANCING ACTIVITIES:
             Repayment of long-term borrowings                                       (38,526)        (36,018)
         -----------------------------------------------------------------------------------------------------

                      Net Cash Used in Financing Activities                          (38,526)        (36,018)

         -----------------------------------------------------------------------------------------------------
         NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS:                        28,451        (398,975)
         Cash and Cash Equivalents at Beginning of Period                            843,610       1,585,765
         -----------------------------------------------------------------------------------------------------
         Cash and Cash Equivalents at End of Period                            $     872,061   $   1,186,790
         -----------------------------------------------------------------------------------------------------

         Non-Cash Investing and Financing Activities:
             Note Receivable in exchange for Sale of Product Lines                              $    400,000
</TABLE>


                            See accompanying notes.
















<PAGE>

                   HYDROMER, INC. AND CONSOLIDATED SUBSIDIARY

                   Notes to Consolidated Financial Statements

In  the  opinion  of management, the accompanying unaudited financial statements
include  all adjustments (consisting of only normal adjustments) necessary for a
fair   presentation   of   the   results   for   the  interim  periods.  Certain
reclassifications  have  been  made  to  the  previous year's results to present
comparable financial statements.

Foreign Currency Translations:

The  Company  accounts for foreign currency translation pursuant to Financial
Accounting Standards Board ("FASB") Accounting Standards Codification
("ASC") 830-20, "Foreign Currency Transaction". The Company's functional
currency is the United States Dollar.  All assets and liabilities are translated
into United States dollars using the rates prevailing at the end of the period.
Revenues and expenses are translated using the average exchange rates prevailing
throughout the period.  Unrealized foreign exchange amounts resulting from
transactions at different rates according to their nature are included in
accumulated other comprehensive income or loss. Recognized foreign currency
transaction gains and losses are recognized in the operations.

Comprehensive Income (Loss):

The  Company  applies  the  provision  of FASB's ASC 220-10, "Reporting
Comprehensive Income." Unrealized gains and losses from  foreign  exchange
translations are reported in the consolidated statements of  shareholders'
deficit as comprehensive income (loss). As of March 31, 2011, there was no
comprehensive income (loss).

Subsequent Events:

Due  to  the  net loss for the nine months ended March 31, 2011, the Company did
not meet two mortgage covenants. A waiver has been granted by the lender for the
period.  Although a waiver was granted by the lender, there is no certainty that
future waivers would be granted.

Significant Events:
On  November  25, 2009, the Company's wholly owned subsidiary, Biosearch Medical
Products,  Inc.  ("BMPI")  sold  its  Private  Label  Jejunostomy  Catheter  and
Nasogastric   Feeding   Catheter  business  to  Forefront  Medical  Technologies
("Forefront"),  a  wholly  owned subsidiary of Vicplas International Limited - a
company  registered  in  the  Republic  of Singapore, for $800,000 in cash, half
received  upon closing in November 2009 with the balance received in March 2010.
This  sale  included  inventory  and equipment related to that business and also
called for the assignment of certain customer supply agreements to Forefront and
a  three year non-compete provision. A separate supply agreement for Hydromer(R)
hydrophilic coating solution used on those products was also entered between the
parties.  BMPI  continued manufacturing the products, at an agreed upon transfer
price, until Forefront completed the transition in April 2010. Accordingly, this
transaction  does  not meet the criteria of Discontinued Operations of ASC
205-20.  These  product  lines  sold  were  part  of  the "Medical Products"
segment (see following Segment Reporting section).

Fair Value:
Some  of the Company's financial instruments are not measured at fair value on a
recurring  basis  but are recorded at amounts that approximate fair value due to
their   liquid  or  short-term  nature,  such  as  cash  and  cash  equivalents,
receivables  and  payables. The carrying amount of the Company's note obligation
approximates  its  fair value, as the terms of the note is consistent with terms
available in the market for instruments with similar risk.

Segment Reporting:
The  Company  operates  two primary business segments. The Company evaluates the
segments  by  revenues,  total  expenses  and  earnings  before taxes. Corporate
Overhead  (primarily  the  salaries  and  benefits of senior management, support
services  (Accounting,  Legal,  Human Resources and Purchasing) and other shared
services  (building  maintenance and warehousing) are excluded from the business
segments  as to not distort the contribution of each segment. These segments are
the  lowest  levels for which identifiable cash flows are largely independent of
the cash flows of other assets and liabilities.





<PAGE>
The results for the nine months ended March 31, by segment are:
<TABLE>
<S>                                              <C>                <C>              <C>              <C>

                                                      Polymer          Medical         Corporate
                                                     Research          Products        Overhead            Total
         2011
         Revenues                                $   3,027,098      $   985,961                       $  4,013,059
         Expenses                                   (2,614,565)        (932,786)     $ (1,220,338)      (4,767,689)
                                                  ---------------  ----------------  -------------  ---------------
              Pre-tax Income (Loss)              $     412,533      $    53,175      $ (1,220,338)    $   (754,630)
                                                  ===============  ================  =============  ===============

         ---------------------------------------- ---------------- ----------------- -------------- ----------------
         2010*
         Revenues                                $   2,936,347      $ 1,664,506                       $  4,600,853
         Expenses                                   (3,000,632)      (1,746,469)     $ (1,190,373)      (5,937,474)
                                                 --------------     ------------     -------------  --------------
            Pre-tax Income (Loss)                $     (64,285)     $   (81,963)     $ (1,190,373)    $ (1,336,621)
                                                 ==============     ============     =============  ==============
</TABLE>


* includes the results of operations of the sold Product Lines but excludes
  the actual Sales transaction.


Geographic revenues were as follows for the nine months ended March 31,

                                                             2011      2010
                                                             ----      ----
                                 Domestic                     59%       72%
                                 Foreign                      41%       28%


ITEM #2

                  MANAGEMENT'S DISCUSSION AND ANALYSIS OF THE
                 FINANCIAL CONDITION AND RESULTS OF OPERATIONS
                 ---------------------------------------------

Results of Operations
---------------------

The  Company's  revenues  for  the quarter ended March 31, 2011 were $1,551,042,
$75,874  or  5.1%  higher  than  the $1,475,168 for the same period the previous
year.  For the nine month period ended March 31, revenues were $4,013,059 during
the  2011  year,  as  compared with $4,600,853 the year before or $587,794 lower
(12.8%). Revenues are comprised of the sale of Products and Services and Royalty
and Contract payments.



      Product  sales  were  $1,070,400  for  the quarter ended March 31, 2011 as
      compared  to  $845,734  for  the  same  period the year before, a $224,666
      (26.6%)  increase:  higher  due  to an increase in Dragonhyde(R) Hoof Bath
      Concentrate  sales  of  $232,636,  primarily  in Europe. The quarter ended
      March  31,  2010  included  $99,181 in transitional sales from the medical
      device  product  lines  sold  in  November 2009. For the nine month period
      ended  March  31,  2011,  product  sales  were $2,281,134 as compared with
      $2,856,840 or $575,706 (20.2%) lower than the same period the year before.
      Sales from the divested product lines (including of the product lines sold
      in  April 2009 with its transition period carrying operations into October
      2010)  accounted  for  approximately $798,074 of the difference, offset by
      $311,856  in  higher  Dragonhyde  Hoof  Bath  Concentrates sales. The 2011
      results  would  have  been  better  had it not been for toll manufacturing
      delays  that prevented over $132,000 of additional sales from occurring in
      March.

      Services  revenues,  primarily  contract  coating  services, for the three
      months  ended  March  31, 2011 was $274,326 or $128,440 lower (31.9%) than
      the  $402,766  the  corresponding period the year before, primarily timing
      differences  as overall, Services revenues for the nine months ended March
      31,  2011  was  $1,044,715 or $17,334 lower (1.6%) than the $1,062,049 the
      corresponding period the year before.



<page>
      Royalty  and Contract revenues include royalties received and the periodic
      recurring  payments  from  license, stand still and other agreements other
      than  for  product and services. Included in Royalty and Contract revenues
      are revenues from support and supply agreements. Some of the royalties and
      support  fees  are  based on the net sales of the final item (to which the
      Hydromer technology is applied to) and are subject to the reporting of our
      customers.  For  the  quarter  ended  March 31, 2011, Royalty and Contract
      revenues  were  $206,316, compared to $226,668 the same period a year ago.
      For  the  nine  months ended March 31, 2011, Royalty and Contract revenues
      were  $687,210,  compared  with  the previous year's $681,964. We continue
      entering  into  new  Royalty  and  Contract revenue agreements, some which
      begin  with  our  customer's  first commercial sale of their product. Once
      online,  including  with  the  commercialization  of  one  of our hydrogel
      technologies,  we  anticipate  a  doubling of this revenue line within the
      next few years.

      When  excluding  the  revenues  from  the  divested  product lines, we are
      reporting  a  5.5%  gain in total revenues this year's period; a 9.0% gain
      had  they  not been any toll manufacturing delays in March 2011. We expect
      continued  revenue  growth,  particularly  in  our T-HEXX(R) Animal Health
      business  where a majority of our research and development during the past
      two years has been focused upon.

Total  Expenses for the quarter ended March 31, 2011 were $1,608,910 as compared
with  $1,681,584  the  year  before,  a 4.3% decrease. For the nine months ended
March  31,  2011, total expenses were $4,523,833 as compared with $5,156,794 the
same  period  the year before, or an improvement of 12.3%. Reducing expenses for
the nine months ended March 31, 2010 was the gain from the sale of product lines
of  $335,629. When excluding the gain from sale of product lines, total expenses
for  the nine months ended March 31, 2010 would have been $5,492,423 or with the
current period $968,590 (17.6%) better.

      For the quarter ended March 31, 2011, the Company's Cost of Goods Sold was
      $483,068  as  compared  with  $526,601 the year prior, lower by $43,533 or
      8.3%.  The  Cost  of  Goods  Sold  attributed  to  the  sold product lines
      approximated   $5,171   in   the  March  2011  quarter  as  compared  with
      approximately  $137,511  in the March 2010 quarter with the cost reduction
      offset  by  the  higher  material  Cost of Goods Sold from the increase in
      [Dragonhyde]  product  sales revenues. The Cost of Goods Sold for the nine
      month  period  was  $1,231,650  or  $762,408 better (38.2%) than the prior
      year's  $1,994,058,  which included approximately $836,744 relating to the
      divested product lines.

      Operating expenses were $1,101,305 for the quarter ended March 31, 2011 as
      compared  with $1,316,952 the year before, lower by $215,647 or 16.4%. For
      the  nine  month  period,  Operating  expenses  were  $3,378,516 this year
      compared  with  $3,804,805  the  year  before,  an improvement of $426,289
      (11.2%).  Most  of  the reduction to Operating expenses related to a lower
      staffing  level,  including  in part due to the divestiture of the medical
      device  product  lines,  as  offset  by  increases  in marketing and sales
      expenses  in our T-HEXX Animal Health business (added tradeshow promotions
      and related travel and marketing expenditures).

      Interest  expense,  interest income and other income are included in Other
      Expenses.  Interest  expense  (on  the mortgage) for the nine months ended
      March   31,   2011   and  March  31,  2010  were  $149,037  and  $152,823,
      respectively.  Included  in  Other Income for the 2010 period was the gain
      from the sale of product lines of $335,629.

A  net loss of $57,868 ($0.01 per share) is reported for the quarter ended March
31,  2011  as  compared  to  a  net  loss of $206,416 ($0.04 per share) the year
before. For the nine months ended March 31, 2011, a net loss of $510,774 ($0.11
per share) is reported compared against a net loss of $555,941 ($0.12 per share)
for the same period year before.

      Despite   sales   being   $587,794   lower  this  year-to-date,  of  which
      approximately  $798,074 was attributable to the sale of the medical device
      product  lines,  expense reductions, including that beyond relating to the
      sold  product lines, totaled $632,961. When excluding the $335,629 gain on
      the sale of product lines and its related tax expense, total expenses were
      approximately  $837,695  lower  this year. The Company expects to continue
      improvements  to  its  results coming from increasing revenues with modest
      increases  to  its expense base, primarily in expanded sales and marketing
      costs, including that of new sales representatives.




<page>
Financial Condition

Working  capital  decreased $61,338 during the three months ended March 31, 2011
and $753,449 during the nine months then ended.

For  the  three  months  ended  March  31,  2011,  operating activities provided
$366,853 in net cash. For the nine month period ended March 31, 2011 net cash of
$122,759 was used.

      The  net  loss,  as  adjusted  for  non-cash  expenses of depreciation and
      amortization  and  deferred  income  taxes, used $451,508 in cash. The net
      change  in  other  operating  assets  and liabilities provided $328,749 in
      cash,  with  the  primarily  activities  being  the  collection  of  trade
      receivables  and  customer  prepayments and increased accounts payable and
      accrued  expenses as offset by higher inventories, in part due to the toll
      manufacturer delays.

Investing  activities  provided  $189,736  and financing activities used $38,526
during the nine months ended March 31, 2011.

      Investing  activities  for  the  nine months ended March 31, 2011 included
      $110,254  for  capital  expenditures  and  $140,010  towards the Company's
      patent   estate.  $440,000  in  short-term  investments  matured  and  was
      converted into cash. Reported under Financing activities was the repayment
      of the principal portion of the mortgage.

For  the  quarter  ended  March  31,  2011,  we  were near break-even. This is a
tremendous  turnaround  following  a  $780,000  annual loss in support fees/cash
effective  January  1,  2009  and an annualized $2 million+ loss in revenues (an
approximate  loss of $400,000+ in pre-tax profits) related to the medical device
product  lines  sold  in  2009.  With  a  continued  market penetration from our
recently  introduced  products  and the medical coatings introduced years prior,
completing  their [clinical] evaluations by our customers, we expect a return to
profitability soon.












































<PAGE>

ITEM # 3

Disclosure Controls and Procedures

   As  of  the  period  covered  by  this  report,  the  Company  carried out an
evaluation,  under the supervision and with the participation of our management,
including  the  Chief  Executive  Officer  and President and the Chief Financial
Officer,  of  the  effectiveness  of  the design and operation of the disclosure
controls and procedures.

    Based  upon this evaluation, our Chief Executive Officer and Chief Financial
Officer  concluded  that,  our disclosure controls and procedures were effective
and  that there were no changes to our Company's internal control over financial
reporting  that  have materially affected, or is reasonably likely to materially
affect the Company's internal control over financial reporting during the period
covered by the Company's quarterly report.

PART II - OTHER INFORMATION

   The Company operates entirely from its sole location at 35 Industrial Parkway
in  Branchburg,  New  Jersey,  an owned facility secured by a mortgage through a
bank.

   The  existing  facility will be adequate for the Company's operations for the
foreseeable future.

ITEM # 6. Exhibits

       Exhibit No.   Description
          31.1       Rule 13a-14(a) Certification of Chief Executive Officer
                     and President
          31.2       Rule 13a-14(a) Certification of Vice President of Finance
                     and Chief Financial  Officer
          32.1       Section  1350  Certification of Chief Executive Officer
                     and Chairman, President
          32.2       Section 1350 Certification of Chief Financial Officer
                     and Vice President of Finance

                                   SIGNATURES

Pursuant  to  the  requirements  of  the  Securities  Exchange  Act of 1934, the
registrant  has  duly  caused  this  report  to  be  signed on his behalf by the
undersigned thereunto duly authorized.

                          HYDROMER, INC.


                          /s/ Robert Lee, VP
                          Robert Y. Lee
                          Principal Accounting Officer & Chief Financial Officer



DATE: May 23, 2011























<PAGE>
                                  EXHIBIT 31.1

I, Manfred F. Dyck, certify that:

1. I have reviewed this quarterly report on Form
   10-Q of Hydromer, Inc.;

2.      Based on my knowledge, this quarterly report does not contain any untrue
        statement  of a material fact or omit to state a material fact necessary
        to  make  the statements made, in light of the circumstances under which
        such  statements  were  made,  not misleading with respect to the period
        covered by this quarterly report;

3.      Based  on  my  knowledge,  the financial statements, and other financial
        information  included  in  this  quarterly report, fairly present in all
        material  respects  the  financial  condition, results of operations and
        cash  flows  of  the registrant as of, and for, the periods presented in
        this quarterly report;

4.      The  registrant's  other  certifying officer, Mr. Robert Y. Lee and I am
        responsible  for  establishing  and  maintaining disclosure controls and
        procedures  (as  defined  in Exchange Act Rules 13a-15(e) and 15d-15(e))
        and  internal  control  over financial reporting (as defined in Exchange
        Act Rules 13a-15(f) and 15d-15(f) for the registrant and have:

      a) designed  such  disclosure  controls  and  procedures,  or  caused such
         disclosure   controls   and   procedures   to  be  designed  under  our
         supervision,  to  ensure  that  material  information  relating  to the
         registrant,  including  its consolidated subsidiaries, is made known to
         us  by  others within those entities, particularly during the period in
         which this quarterly report is being prepared;

      b) designed  such  internal  controls  over financial reporting, or caused
         such  internal  controls  over financial reporting to be designed under
         our   supervision,  to  provide  reasonable  assurances  regarding  the
         reliability  of  financial  reporting  and the preparation of financial
         statements  for external purposes in accordance with generally accepted
         accounting principles

      c) evaluated the effectiveness of the registrant's disclosure controls and
         procedures  and  presented  in  this  report  our conclusions about the
         effectiveness  of the disclosure controls and procedures, as of the end
         of the period covered by this report based on such evaluation; and

      d) disclosed  in  this  report  any  change  in  the registrant's internal
         control  over financial reporting that occurred during the registrant's
         most  recent  fiscal quarter (the registrant's fourth fiscal quarter in
         case  of  an  annual  report)  that  has  materially  affected,  or  is
         reasonably  likely  to  materially  affect,  the  registrant's internal
         control over financial reporting;

5.      The  registrant's other certifying officer, Mr. Robert Y. Lee and I have
        disclosed,  based  on  our  most  recent evaluation, to the registrant's
        auditors  and the audit committee of registrant's board of directors (or
        persons performing the equivalent functions):

      a) all  significant  deficiencies  in  the design or operation of internal
         controls  which  could  adversely  affect  the  registrant's ability to
         record,   process,   summarize  and  report  financial  data  and  have
         identified  for  the  registrant's  auditors any material weaknesses in
         internal controls; and

      b) any  fraud,  whether or not material, that involves management or other
         employees  who  have  a  significant  role in the registrant's internal
         controls; and

6.      The  registrant's other certifying officer, Mr. Robert Y. Lee and I have
        indicated  in  this  quarterly  report  whether  there  were significant
        changes   in   internal   controls   or  in  other  factors  that  could
        significantly  affect  internal  controls  subsequent to the date of our
        most  recent evaluation, including any corrective actions with regard to
        significant deficiencies and material weaknesses.

Date: May 23, 2011

/s/ Manfred F. Dyck
--------------------------------------
Manfred F. Dyck, President and CEO
<PAGE>
                                  EXHIBIT 31.2

I, Robert Y. Lee, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Hydromer, Inc.;

2.      Based on my knowledge, this quarterly report does not contain any untrue
        statement  of a material fact or omit to state a material fact necessary
        to  make  the statements made, in light of the circumstances under which
        such  statements  were  made,  not misleading with respect to the period
        covered by this quarterly report;

3.      Based  on  my  knowledge,  the financial statements, and other financial
        information  included  in  this  quarterly report, fairly present in all
        material  respects  the  financial  condition, results of operations and
        cash  flows  of  the registrant as of, and for, the periods presented in
        this quarterly report;

4.      The  registrant's other certifying officer, Mr. Manfred F. Dyck and I am
        responsible  for  establishing  and  maintaining disclosure controls and
        procedures  (as  defined  in Exchange Act Rules 13a-15(e) and 15d-15(e))
        and  internal  control  over financial reporting (as defined in Exchange
        Act Rules 13a-15(f) and 15d-15(f) for the registrant and have:

      a) designed  such  disclosure  controls  and  procedures,  or  caused such
         disclosure   controls   and   procedures   to  be  designed  under  our
         supervision,  to  ensure  that  material  information  relating  to the
         registrant,  including  its consolidated subsidiaries, is made known to
         us  by  others within those entities, particularly during the period in
         which this quarterly report is being prepared;

      b) designed  such  internal  controls  over financial reporting, or caused
         such  internal  controls  over financial reporting to be designed under
         our   supervision,  to  provide  reasonable  assurances  regarding  the
         reliability  of  financial  reporting  and the preparation of financial
         statements  for external purposes in accordance with generally accepted
         accounting principles

      c) evaluated the effectiveness of the registrant's disclosure controls and
         procedures  and  presented  in  this  report  our conclusions about the
         effectiveness  of the disclosure controls and procedures, as of the end
         of the period covered by this report based on such evaluation; and

      d) disclosed  in  this  report  any  change  in  the registrant's internal
         control  over financial reporting that occurred during the registrant's
         most  recent  fiscal quarter (the registrant's fourth fiscal quarter in
         case  of  an  annual  report)  that  has  materially  affected,  or  is
         reasonably  likely  to  materially  affect,  the  registrant's internal
         control over financial reporting;

5.      The  registrant's  other  certifying  officer, Mr. Manfred F. Dyck and I
        have disclosed, based on our most recent evaluation, to the registrant's
        auditors  and the audit committee of registrant's board of directors (or
        persons performing the equivalent functions):

      a) all  significant  deficiencies  in  the design or operation of internal
         controls  which  could  adversely  affect  the  registrant's ability to
         record,   process,   summarize  and  report  financial  data  and  have
         identified  for  the  registrant's  auditors any material weaknesses in
         internal controls; and

      b) any  fraud,  whether or not material, that involves management or other
         employees  who  have  a  significant  role in the registrant's internal
         controls; and

6.      The  registrant's  other  certifying  officer, Mr. Manfred F. Dyck and I
        have  indicated  in this quarterly report whether there were significant
        changes   in   internal   controls   or  in  other  factors  that  could
        significantly  affect  internal  controls  subsequent to the date of our
        most  recent evaluation, including any corrective actions with regard to
        significant deficiencies and material weaknesses.

Date: May 23, 2011

/s/ Robert Lee, VP
--------------------------------------

Robert Y. Lee, Vice President of Finance and CFO
<PAGE>

                                  EXHIBIT 32.1

                    CERTIFICATION OF CHIEF EXECUTIVE OFFICER
                                  PURSUANT TO
                            18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT TO
                 SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002


I,  Manfred  F.  Dyck,  certify,  pursuant to 18 U.S.C. Section 1350, as adopted
pursuant  to  Section  906 of the Sarbanes-Oxley Act of 2002, that the Quarterly
Report  of  Hydromer, Inc. on Form 10-Q for the nine months ended March 31, 2011
fully complies with the requirements of Section 13(a) or 15(d) of the Securities
Exchange  Act  of  1934  and  that  information  contained in such report fairly
presents  in  all  material  respects  the  financial  condition  and results of
operations of Hydromer, Inc.

Date: May 23, 2011           By: /s/ Manfred F. Dyck
                                 Manfred F. Dyck
                                 Chairman, President and Chief Executive Officer

--------------------------------------------------------------------------------

                                  EXHIBIT 32.2

                    CERTIFICATION OF CHIEF FINANCIAL OFFICER
                                  PURSUANT TO
                            18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT TO
                 SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002


I,  Robert  Y.  Lee,  certify,  pursuant  to  18 U.S.C. Section 1350, as adopted
pursuant  to  Section  906 of the Sarbanes-Oxley Act of 2002, that the Quarterly
Report  of  Hydromer, Inc. on Form 10-Q for the nine months ended March 31, 2011
fully complies with the requirements of Section 13(a) or 15(d) of the Securities
Exchange  Act  of  1934  and  that  information  contained in such report fairly
presents  in  all  material  respects  the  financial  condition  and results of
operations of Hydromer, Inc.

Date: May 23, 2011     By: /s/ Robert Lee, VP
                           Robert Y. Lee
                           Chief Financial Officer and Vice President of Finance